Qiagen will publish its fourth quarter 2025 financial results on Wednesday, February 4, shortly after 22:05 CET (21:05 GMT, 16:05 EST). The company will host a live webcast and conference call on Thursday, February 5 at 15:30 CET (14:30 GMT, 09:30 EST) to discuss performance highlights, including revenue growth trends in molecular diagnostics and sample technologies. Participants can register for a call-back connection or dial in via U.S., U.K. and German numbers using Conference ID 3382302; a replay will be available online. As of September 30, 2025, Qiagen employed approximately 5,700 staff across more than 35 locations and served over 500,000 customers globally, underscoring its scale in Life Sciences and Molecular Diagnostics markets. Qiagen N.V. is conducting a strategic review of its diagnostics business as it explores options to enhance shareholder value, Bloomberg reported on Tuesday, citing people familiar with the matter. The review includes the possibility of a full sale or partial divestiture of its molecular diagnostics division. Sources indicate that multiple private equity firms and industry peers have expressed preliminary interest in acquiring the business, valuing the unit at over $5 billion based on recent sector transactions. The board has engaged financial advisers to evaluate binding and non‐binding proposals, with a decision expected by mid‐2026. Investors are watching closely, as any transaction could significantly reshape Qiagen’s product portfolio and capital allocation strategy.